Could GLP-1 Drugs Make ResMed's CPAP Machines Obsolete?
ResMed (NYSE: RMD) finds itself in an investment limbo as revolutionary weight loss drugs create both immediate opportunities and long-term existential questions for the sleep apnea device maker.
The company, a leading manufacturer of CPAP machines used to treat sleep apnea, faces a nuanced challenge from GLP-1-based medications. The core issue: obesity drives the vast majority of obstructive sleep apnea cases, with 70-90% of sufferers experiencing the condition due to excess weight. As patients lose weight through GLP-1 treatments, their need for breathing assistance devices may disappear entirely.
Source Fool.com
Resmed Inc. Aktie
203,20 €
1,40 %
Eine klare Tendenz zu Buy-Einschätzungen bei Resmed Inc., ohne Sell-Einschätzungen.
Ein Kursziel von 256 € für Resmed Inc. könnte zu einer Steigerung von mehr als 20% gegenüber dem aktuellen Kurs von 203.2 € führen.
